tiprankstipranks
Trending News
More News >

Satsuma Pharmaceuticals Gains FDA Approval for Migraine Treatment

Story Highlights
Satsuma Pharmaceuticals Gains FDA Approval for Migraine Treatment

Don’t Miss TipRanks’ Half-Year Sale

Shin Nippon Biomedical Laboratories, Ltd. ( (JP:2395) ) has issued an update.

Satsuma Pharmaceuticals, a subsidiary of SNBL, has received U.S. FDA approval for Atzumi™, a nasal powder for the acute treatment of migraines. This approval marks a significant milestone for SNBL, showcasing their innovative intranasal drug delivery platform and potentially enhancing the quality of life for migraine sufferers.

More about Shin Nippon Biomedical Laboratories, Ltd.

Shin Nippon Biomedical Laboratories, Ltd. (SNBL) is a Japanese nonclinical contract research organization founded in 1957, offering a range of services for drug discovery and development. Its subsidiary, Satsuma Pharmaceuticals, focuses on creating therapeutic products for unmet medical needs, particularly in drug-device combination products delivered via inhalation.

YTD Price Performance: -14.07%

Average Trading Volume: 349,813

Technical Sentiment Signal: Buy

Current Market Cap: Yen58.49B

See more insights into 2395 stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1